GB Sciences (GBLX) 10-Q 13 Nov 20 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Sep. 30, 2020	Nov. 13, 2020
Document Information [Line Items]
Entity Registrant Name	GB SCIENCES INC
Entity Central Index Key	0001165320
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		281,779,436
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Mar. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 545,020	$ 2,406
Prepaid expenses and other current assets	18,776	18,776
Note receivable	4,350,000	5,224,423
Current assets from discontinued operations	1,997,037	1,755,275
TOTAL CURRENT ASSETS	6,910,833	7,000,880
Property and equipment, net	31,278	37,821
Intangible assets, net of accumulated amortization of $17,611 and $12,287 at September 30, 2020 and March 31, 2020, respectively	1,545,355	1,128,702
Long term assets from discontinued operations	5,766,598	6,185,465
TOTAL ASSETS	14,254,064	14,352,868
CURRENT LIABILITIES:
Accounts payable	2,346,652	1,913,049
Accrued interest	479,255	366,865
Accrued liabilities	1,205,248	813,618
Notes and convertible notes payable and line of credit, net of unamortized discount of $9,624 and $608,580 at September 30, 2020 and March 31, 2020, respectively	6,428,278	5,054,728
Indebtedness to related parties	710,075	586,512
Note payable to related party		151,923
Income tax payable	620,856	592,982
Current liabilities from discontinued operations	1,348,111	1,406,080
TOTAL CURRENT LIABILITIES	13,138,475	10,885,757
Long term liabilities from discontinued operations	3,465,160	3,555,605
TOTAL LIABILITIES	16,603,635	14,441,362
Commitments and contingencies (Note 8)
STOCKHOLDERS' DEFICIT:
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 280,532,686 and 275,541,602 outstanding at September 30, 2020 and March 31, 2020, respectively	28,054	27,554
Additional paid-in capital	97,679,001	97,271,157
Accumulated deficit	(100,056,626)	(97,387,205)
TOTAL STOCKHOLDERS' DEFICIT	(2,349,571)	(88,494)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 14,254,064	$ 14,352,868

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2020	Mar. 31, 2020
Intangible assets, accumulated amortization	$ 17,611	$ 12,287
Notes and convertible notes payable, unamortized discount, current	$ 9,624	$ 608,580
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	280,532,686	275,541,602
Common stock, shares outstanding (in shares)	280,532,686	275,541,602

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Sales revenue
Cost of goods sold
Gross profit
General and administrative expenses	491,818	1,291,232	1,007,071	3,082,697
LOSS FROM OPERATIONS	(491,818)	(1,291,232)	(1,007,071)	(3,082,697)
OTHER INCOME/(EXPENSE)
Interest expense	(410,946)	(352,736)	(1,082,874)	(664,937)
Debt default penalty			(286,059)
Other income/(expense)	(1,750)	92,707	(3,374)	92,707
Total other expense	(412,696)	(260,029)	(1,372,307)	(572,230)
LOSS BEFORE INCOME TAXES	(904,514)	(1,551,261)	(2,379,378)	(3,654,927)
Income tax benefit/(expense)	(19,034)	57,392	(27,874)
LOSS FROM CONTINUING OPERATIONS	(923,548)	(1,493,869)	(2,407,252)	(3,654,927)
Gain/(loss) from discontinued operations	118,090	(1,434,737)	(244,906)	(1,812,563)
NET LOSS	(805,458)	(2,928,606)	(2,652,158)	(5,467,490)
Net loss attributable to non-controlling interest		(245,565)		(377,781)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	(805,458)	(2,683,041)	(2,652,158)	(5,089,709)
Continuing operations	(923,548)	(1,493,869)	(2,407,252)	(3,654,927)
Discontinued operations	118,090	(1,189,172)	(244,906)	(1,434,782)
Net loss	$ (805,458)	$ (2,683,041)	$ (2,652,158)	$ (5,089,709)
Continuing operations (in dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.01)
Discontinued operations (in dollars per share)	0	0	0	(0.01)
Net loss (in dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Weighted average common shares outstanding - basic and diluted (in shares)	280,532,686	252,700,538	279,257,607	248,392,203

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Mar. 31, 2020USD ($)
OPERATING ACTIVITIES:
Net loss	$ (805,458)	$ (2,928,606)	$ (2,652,158)	$ (5,467,490)
Loss from discontinued operations	118,090	(1,434,737)	(244,906)	(1,812,563)
Net loss from continuing operations			(2,407,252)	(3,654,927)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			15,612	76,716
Stock-based compensation				341,724
Amortization of debt discount and beneficial conversion feature			748,956	434,750
Interest expense on conversion of notes payable				26,804
Loss on extinguishment				124,158
Default penalty on convertible note payable			286,059
Changes in operating assets and liabilities:
Prepaid expenses and other current assets				180,060
Accounts payable			262,881	304,550
Accrued expenses			414,130	187,133
Accrued interest			325,925	190,695
Income tax payable			27,874
Indebtedness to related parties			123,563
Net cash used in operating activities of continuing operations			(202,252)	(1,788,337)
Net cash used in operating activities of discontinued operations			(10,602)	(1,758,120)
Net cash used in operating activities			(212,854)	(3,546,457)
INVESTING ACTIVITIES:
Proceeds from note receivable			701,923
Acquisition of intangible assets				(91,862)
Net cash provided/(used) in investing activities of continuing operations			701,923	(91,862)
Net cash used in investing activities of discontinued operations			(104,265)	(462,920)
Net cash provided/(used) in investing activities			597,658	(554,782)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock				550,225
Gross proceeds from warrant exercises			151,202	944,975
Gross proceeds from convertible notes payable			150,000	2,600,000
Proceeds from Line of Credit			125,000
Principal payment on note payable to related party			(151,923)
Fees for issuance of convertible note				(175,000)
Brokerage fees for issuance of common stock and warrants			(15,121)	(166,027)
Net cash provided by financing activities of continuing operations			259,158	3,754,173
Net cash provided/(used) in financing activities of discontinued operations			(101,487)	213,625
Net cash provided by financing activities			157,671	3,967,798
Net change in cash and cash equivalents			542,475	(133,441)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD			151,766	227,758	$ 227,758
CASH AND CASH EQUIVALENTS AT END OF PERIOD	694,241	94,317	694,241	94,317	$ 151,766
Less: cash and cash equivalents classified as discontinued operations	(149,221)	(23,639)	(149,221)	(23,639)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	$ 545,020	$ 70,678	545,020	70,678
Cash paid for interest				332,167
Cash paid for income tax
Non-cash transactions:
Accrued liabilities forgiven in connection with Wellcana Note letter agreement			172,500
Depreciation capitalized in inventory			272,267	273,090
Accrued interest capitalized in convertible note principal			223,094
Property capitalized under operating leases				182,624
Patent acquisition costs capitalized in intangible assets			320,722	67,008
Stock options issued to acquire intangible assets			105,000
Stock issued upon conversion of notes payable				280,000
Induced dividend from warrant exercises			17,263	230,025
Cumulative effect of the new lease standard				7,550
Convertible Notes Payable [Member]
Non-cash transactions:
Beneficial conversion feature on notes payable			$ 150,000	$ 133,806

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Noncontrolling Interest [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Mar. 31, 2019						240,627,102
Balance (Accounting Standards Update 2016-02 [Member]) at Mar. 31, 2019			$ (7,550)		$ (7,550)
Balance at Mar. 31, 2019						$ 24,063	$ 93,020,015	$ (84,743,836)	$ 8,855,757	$ 17,155,999
Net loss								(5,089,709)	(377,781)	(5,467,490)
Issuance of stock for debt conversion (in shares)						2,000,000
Issuance of stock for debt conversion						$ 200	279,800			280,000
Exercise of warrants for stock (in shares)						9,449,750
Exercise of warrants for stock						$ 945	849,533			850,478
Share based compensation expense							208,809			208,809
Beneficial conversion feature on notes payable							133,806			133,806
Contributions from non-controlling interest									550,001	550,001
Compensation warrants							132,914			132,914
Inducement dividend from warrant exercises							230,025	(230,025)
Issuance of stock for cash, net of issuance costs (in shares)						3,668,167
Issuance of stock for cash, net of issuance costs						$ 367	478,329			478,696
Cancelled shares issued to consultant (in shares)						(400,000)
Cancelled shares issued to consultant						$ (40)	40
Balance (in shares) at Sep. 30, 2019						255,345,019
Balance at Sep. 30, 2019						$ 25,535	95,333,271	(90,071,120)	9,027,977	14,315,663
Balance (in shares) at Jun. 30, 2019						246,852,769
Balance at Jun. 30, 2019						$ 24,686	94,095,065	(87,232,454)	8,723,541	15,610,838
Net loss								(2,683,041)	(245,565)	(2,928,606)
Issuance of stock for debt conversion (in shares)						1,000,000
Issuance of stock for debt conversion						$ 100	109,900			110,000
Exercise of warrants for stock (in shares)						7,492,250
Exercise of warrants for stock						$ 749	673,553			674,302
Share based compensation expense							32,408			32,408
Beneficial conversion feature on notes payable							133,806			133,806
Contributions from non-controlling interest									550,001	550,001
Compensation warrants							132,914			132,914
Inducement dividend from warrant exercises							155,625	(155,625)
Balance (in shares) at Sep. 30, 2019						255,345,019
Balance at Sep. 30, 2019						$ 25,535	95,333,271	(90,071,120)	9,027,977	14,315,663
Balance (in shares) at Mar. 31, 2020						275,541,602
Balance at Mar. 31, 2020						$ 27,554	97,271,157	(97,387,205)		(88,494)
Stock options issued to acquire intangible assets							105,000			105,000
Net loss								(2,652,158)		(2,652,158)
Exercise of warrants for stock (in shares)						4,991,084
Exercise of warrants for stock						$ 500	135,581			136,081
Beneficial conversion feature on notes payable							150,000			150,000
Inducement dividend from warrant exercises							17,263	(17,263)
Balance (in shares) at Sep. 30, 2020						280,532,686
Balance at Sep. 30, 2020						$ 28,054	97,679,001	(100,056,626)		(2,349,571)
Balance (in shares) at Jun. 30, 2020						280,532,686
Balance at Jun. 30, 2020						$ 28,054	97,574,001	(99,251,168)		(1,649,113)
Stock options issued to acquire intangible assets							105,000			105,000
Net loss								(805,458)		(805,458)
Balance (in shares) at Sep. 30, 2020						280,532,686
Balance at Sep. 30, 2020						$ 28,054	$ 97,679,001	$ (100,056,626)		$ (2,349,571)

Note 1 - Background and Signifi

Note 1 - Background and Significant Accounting Policies	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1 GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) seeks to be a biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. The Company is engaged in the research and development of cannabinoid medicines and plans to produce cannabinoid therapies for the wellness markets based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of cannabinoid medicines with virtual operations in North America and Europe. GBSGB assets include cannabinoid medicine intellectual property, research contracts and key supplier arrangements. GBSGB's intellectual property covers a range of conditions and several programs are in pre-clinical animal stage of development; including Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB's intellectual property portfolio includes two five four one 2020, three 28 Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2021. March 31, 2020 not 10 March 31, 2020 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts to conform to the current period presentation. Certain items on the unaudited balance sheets and statements of operations and cash flows have been reclassified to conform with current period presentation. The assets, liabilities, income, and cash flows of GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified to discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 10 11 Discontinued Operations Refer to Note 3. Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not No September 30, 2020 Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not Earnings/(loss) per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 153,637,853 158,404,020 September 30, 2020 March 31, 2020 not Recent Accounting Pronouncements Recently Adopted Standards In June 2016, No. 2016 13, 326 2016 13" 326 326 326 2016 13 not not December 15, 2022, In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, April 1, 2020. not All other newly issued accounting pronouncements but not not

Note 2 - Going Concern

Note 2 - Going Concern	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company's financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $ ( 100,056,626 September 30, 2020 ( 6,227,642 September 30, 2020 648,926 ( 3,884,877 March 31, 2020 349,195 ( 212,854 six September 30, 2020 ( 10,602 ( 3,546,457 ( 1,758,120 six September 30, 2019 Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not may

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 3 Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 10 11 There were no September 30, 2020 March 31, 2020 November 15, 2019 September 30, 2020 March 31, 2020 September 30, 2020 March 31, 2020 Continuing Nevada Subsidiaries Total Continuing Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 545,020 $ 149,221 $ 694,241 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 346,058 346,058 - 117,967 117,967 Inventory, net - 1,439,320 1,439,320 - 1,445,839 1,445,839 Prepaid and other current assets 18,776 62,438 81,214 18,776 42,109 60,885 Note receivable 4,350,000 - 4,350,000 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 4,913,796 1,997,037 6,910,833 5,245,605 1,755,275 7,000,880 Property and equipment, net 31,278 5,113,829 5,145,107 37,821 5,496,012 5,533,833 Intangible assets, net 1,545,355 571,265 2,116,620 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 81,504 81,504 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 6,490,429 $ 7,763,635 $ 14,254,064 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 2,346,652 $ 607,766 $ 2,954,418 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 479,255 79,123 558,378 366,865 30,787 397,652 Accrued expenses 1,205,248 48,010 1,253,258 813,618 74,394 888,012 Notes payable, net 6,428,278 485,000 6,913,278 5,054,728 480,000 5,534,728 Indebtedness to related parties 710,075 - 710,075 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable 620,856 - 620,856 592,982 - 592,982 Finance lease obligations, current - 128,212 128,212 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 11,790,364 1,348,111 13,138,475 9,479,677 1,406,080 10,885,757 Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,465,160 3,465,160 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 11,790,364 $ 4,813,271 $ 16,603,635 $ 9,479,677 $ 4,961,685 $ 14,441,362 Discontinued Operations - Revenues and Expenses The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three six September 30, 2020 2019 For the Three Months Ended September 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,264,271 $ 1,264,271 $ - $ 1,548,705 $ 1,548,705 Cost of goods sold - (859,068 ) (859,068 ) - (2,237,779 ) (2,237,779 ) Gross profit/(loss) - 405,203 405,203 - (689,074 ) (689,074 ) General and administrative expenses 491,818 81,464 573,282 1,291,232 536,814 1,828,046 INCOME/(LOSS) FROM OPERATIONS (491,818 ) 323,739 (168,079 ) (1,291,232 ) (1,225,888 ) (2,517,120 ) OTHER INCOME/(EXPENSE) Interest expense (410,946 ) (128,201 ) (539,147 ) (352,736 ) (185,599 ) (538,335 ) Other income/(expense) (1,750 ) (77,448 ) (79,198 ) 92,707 (23,250 ) 69,457 Total other expense (412,696 ) (205,649 ) (618,345 ) (260,029 ) (208,849 ) (468,878 ) INCOME/(LOSS) BEFORE INCOME TAXES (904,514 ) 118,090 (786,424 ) (1,551,261 ) (1,434,737 ) (2,985,998 ) Income tax expense (19,034 ) - (19,034 ) 57,392 - 57,392 NET INCOME/(LOSS) $ (923,548 ) $ 118,090 $ (805,458 ) $ (1,493,869 ) $ (1,434,737 ) $ (2,928,606 ) For the Six Months Ended September 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,815,468 $ 1,815,468 $ - $ 2,459,381 $ 2,459,381 Cost of goods sold - (1,350,863 ) (1,350,863 ) - (2,862,148 ) (2,862,148 ) Gross profit/(loss) - 464,605 464,605 - (402,767 ) (402,767 ) General and administrative expenses 1,007,071 370,920 1,377,991 3,082,697 1,012,737 4,095,434 INCOME/(LOSS) FROM OPERATIONS (1,007,071 ) 93,685 (913,386 ) (3,082,697 ) (1,415,504 ) (4,498,201 ) OTHER INCOME/(EXPENSE) Interest expense (1,082,874 ) (261,143 ) (1,344,017 ) (664,937 ) (373,809 ) (1,038,746 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other income/(expense) (3,374 ) (77,448 ) (80,822 ) 92,707 (23,250 ) 69,457 Total other expense (1,372,307 ) (338,591 ) (1,710,898 ) (572,230 ) (397,059 ) (969,289 ) LOSS BEFORE INCOME TAXES (2,379,378 ) (244,906 ) (2,624,284 ) (3,654,927 ) (1,812,563 ) (5,467,490 ) Income tax expense (27,874 ) - (27,874 ) - - - NET LOSS $ (2,407,252 ) $ (244,906 ) $ (2,652,158 ) $ (3,654,927 ) $ (1,812,563 ) $ (5,467,490 ) Discontinued Operations - Revenues and Expenses (continued) The components of revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three six September 30, 2020 2019 For the Three Months Ended September 30, 2020 2019 GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations Sales revenue $ - $ 1,264,271 $ 1,264,271 $ 377,007 $ 1,171,698 $ 1,548,705 Cost of goods sold - (859,068 ) (859,068 ) (380,629 ) (1,857,150 ) (2,237,779 ) Gross profit/(loss) - 405,203 405,203 (3,622 ) (685,452 ) (689,074 ) General and administrative expenses - 81,464 81,464 424,732 112,082 536,814 INCOME/(LOSS) FROM OPERATIONS - 323,739 323,739 (428,354 ) (797,534 ) (1,225,888 ) OTHER EXPENSE Interest expense - (128,201 ) (128,201 ) (62,777 ) (122,822 ) (185,599 ) Other expense - (77,448 ) (77,448 ) - (23,250 ) (23,250 ) Total other expense - (205,649 ) (205,649 ) (62,777 ) (146,072 ) (208,849 ) INCOME/(LOSS) BEFORE INCOME TAXES - 118,090 118,090 (491,131 ) (943,606 ) (1,434,737 ) Income tax expense - - - - - - NET INCOME/(LOSS) $ - $ 118,090 $ 118,090 $ (491,131 ) $ (943,606 ) $ (1,434,737 ) For the Six Months Ended September 30, 2020 2019 GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations Sales revenue $ - $ 1,815,468 $ 1,815,468 $ 377,007 $ 2,082,374 $ 2,459,381 Cost of goods sold - (1,350,863 ) (1,350,863 ) (380,629 ) (2,481,519 ) (2,862,148 ) Gross profit/(loss) - 464,605 464,605 (3,622 ) (399,145 ) (402,767 ) General and administrative expenses - 370,920 370,920 626,571 386,166 1,012,737 INCOME/(LOSS) FROM OPERATIONS - 93,685 93,685 (630,193 ) (785,311 ) (1,415,504 ) OTHER EXPENSE Interest expense - (261,143 ) (261,143 ) (125,372 ) (248,437 ) (373,809 ) Debt default penalty - - - - - - Other expense - (77,448 ) (77,448 ) - (23,250 ) (23,250 ) Total other expense - (338,591 ) (338,591 ) (125,372 ) (271,687 ) (397,059 ) LOSS BEFORE INCOME TAXES - (244,906 ) (244,906 ) (755,565 ) (1,056,998 ) (1,812,563 ) Income tax expense - - - - - - NET LOSS $ - $ (244,906 ) $ (244,906 ) $ (755,565 ) $ (1,056,998 ) $ (1,812,563 ) Discontinued Operations - Inventory Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's unaudited condensed consolidated balance sheets at September 30, 2020 March 31, 2020 September 30, 2020 March 31, 2020 Raw materials $ 2,677 $ 91,465 Work in progress 789,482 1,166,511 Finished goods 653,314 466,319 Subtotal 1,445,473 1,724,295 Allowance to reduce inventory to net realizable value (6,153 ) (278,456 ) Total inventory, net $ 1,439,320 $ 1,445,839 Discontinued Operations - Leases The Company determines if an arrangement is a lease at inception and has lease agreements for warehouses, office facilities, and equipment. These commitments have remaining non-cancelable lease terms, with lease expirations which range from 2024 2025. As a result of the adoption of ASC 842, $182,624, $190,173 April 1, 2019, Operating leases are included in other current assets , accrued liabilities, and operating lease obligations, long term on the unaudited condensed consolidated balance sheets. Finance leases are included in property and equipment, finance lease obligations, short term, and finance lease obligations, long term, on the unaudited condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% 11.5%. 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not All finance costs recorded in the Company's unaudited condensed consolidated financial statements for the three six September 30, 2020 2019 six September 30, 2020 $286,436, $209,086 $77,350 Operating lease costs included in continuing operations were $3,243, $1,242 $2,001 September 30, 2020, Amortization of lease assets is included in general and administrative expenses. As of September 30, 2020, no September 30, 2020 Year Ending March 31, Finance Leases 2021 (6 months) $ 266,188 2022 544,296 2023 560,625 2024 577,444 2025 594,767 Thereafter 3,781,102 Total minimum lease payments 6,324,422 Less: Amount representing interest (2,731,050 ) Present value of minimum lease payments 3,593,372 Less: Current maturities of capital lease obligations (128,212 ) Long-term capital lease obligations $ 3,465,160

Note 4 - Leases (Continuing Ope

Note 4 - Leases (Continuing Operations)	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Lessee, Operating and Finance Leases [Text Block]	Note 4 As a result of the adoption of ASC 842, $182,624, $190,173 April 1, 2019, Operating leases are included in other current assets and operating lease obligations, short and long term on the unaudited condensed consolidated balance sheets. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not There are no $3,243, $1,242 $2,001 September 30, 2020, no

Note 5 - Notes Payable and Line

Note 5 - Notes Payable and Line of Credit	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 0% October 23, 2017 On October 23, 2017, 100% 100% one $500,000 0% $700,000 three January 1, 2018. $521,067 20.3% $178,933 To date, the company has made principal payments totaling $330,555 $369,445 September 30, 2020 six September 30, 2020 $12,009 September 30, 2020 $ ( 1,919 On August 10, 2020, 11 $190,272 July 31, 2021, no no 15% 8% November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 11 $470,000 September 30, 2020 485,000 $15,000. $19,420 six September 30, 2020 485,000 September 30, 2020 8% May 7, 2020 On May 7, 2020, $135,000 15,000 $150,000 8.0% first $8,000,000 10 11 8,002,500 $0.04. $272,085 $49,525 $222,560. 150,000 six September 30, 2020 $154,964 $4,964 $150,000 September 30, 2020 $0. October 5, 2020. 8% July 24, 2020 On July 24, 2020, 8% "July 24 $500,000 may 8% February 28, 2019 ( 6 July 24 $4,000,000 11 3 July 24 may may September 30, 2020 $125,000. $1,162 six September 30, 2020 Summary of Notes and Convertible Notes Payable As of September 30, 2020 As of September 30, 2020 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (1,919 ) $ 367,526 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 125,000 - 125,000 8% Note Payable dated May 7, 2020 (Note 5) 150,000 - 150,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (7,705 ) 1,249,295 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 - 1,271,863 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 3,264,594 - 3,264,594 Total short-term notes payable 6,922,902 (9,624 ) 6,913,278 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short-term notes payable classified as continuing operations $ 6,437,902 $ (9,624 ) $ 6,428,278

Note 6 - Convertible Notes

Note 6 - Convertible Notes	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Convertible Debt [Text Block]	Note 6 March 2017 $2M In March 2017, third $1,000 6% 4,000 $0.25 4,000 $0.60 three March 2017 May 2017, $2,000,000. three 8,000,000 8,000,000 one $0.60 three $1,933,693, $904,690 $1,029,003 July 2017 $7.2M In July, 2017, third $1,000 6% 4,000 $0.25 4,000 $0.65 three July 2017 December 2017, $7,201,000. three 28,804,000 28,804,000 one $0.60 three $7,092,796, $3,142,605 $3,950,191 As of September 30, 2020 1,249,295 ( 7,705 March 2017 July 2017 $234,998. six September 30, 2020 $185,448, $147,635 As of September 30, 2020 $997,000 March July 2017 not 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, $1,500,000 8% August 28, 2020 8,823,529 $0.17 100% $176,471 On May 28, 2019, $170,000 8% February 28, 2019. 1,000,000 $0.17 $17,225 $152,775. $1,330,000. On July 12, 2019, 8% $100,000 $100,000 July 12, 2019 $41,863 $0.11 The Company evaluated the modification under the guidance in ASC 470 50 10% $1,338,057, $133,806, $124,158. On August 1, 2019, 110,000 $0.11 1,000,000 $9,579 $100,421. 1,361,863. On October 23, 2019, October 23, 2019 $0.08 We evaluated the modification under the guidance in ASC 470 50 10% 2nd $1,269,067, $92,796, $92,796 March 31, 2020. On November 27, 2019, 8% “2nd 2nd $0.04 $30,000 We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd no 2nd $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 During the six September 30, 2020 $460,495 $51,014 $409,481 September 30, 2020 1,271,863 no The Company defaulted on the amended CSW Note due to non-payment of quarterly interest payments and for nonpayment of an income tax liability related to the March 31, 2018 5 ten 11 8% April 23, 2019 On April 23, 2019, 8% $2,765,000. $265,000 $0.17 April 22, 2020. $440,000 $265,000 $175,000 During the year ended March 31, 2020, $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 On April 22, 2020, 10%. $9,559 10% $276,500 10% On May 20, 2020, not July 14, 2020, $3,264,594 15% not 10 During the six September 30, 2020 $275,310, $29,831 $140,833 $104,646 no $3,264,594.

Note 7 - Capital Transactions

Note 7 - Capital Transactions	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 7 Sale of Common Stock and Exercise of Warrants On April 1, 2020, $0.03 $.05 4,991,084 six September 30, 2020 136,081 ( 15,121 During the quarter ended September 30, 2020 3,500,000 one $0.03 ten $105,000 At September 30, 2020 79,488,161 $0.25 $1.00 13,366,334 $0.28

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8 On September 18, 2017 five two five The contract includes the Company's commitment to make an annual research investments of $500,000 50% 10 $250,000 $500,000 three $750,000. September one August 4, 2020, first $250,000 twelve September 30, 2020, twelve 50% 50% 25% On August 24, 2020, $250,000 no 10 Tara “Dee” Russell filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, May 15, 2019. July 26, 2019. not not On April 22, 2020, 6 May 20, 2020, July 14, 2020, $3,264,594 15% not 10 September 30, 2020 $3,369,240 $104,646 On April 22, 2020, $73,050 September 17, 2020, $25,000 $48,050. From time to time, the Company may not

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 9 As of September 30, 2020 710,075 $532,130 $112,087 $65,858 In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $ 151,923 first 10 August 4, 2020, first

Note 10 - Sale of Membership In

Note 10 - Sale of Membership Interests in GB Sciences Louisiana, LLC	6 Months Ended
	Sep. 30, 2020
GB Sciences Louisiana, LLC, Sale of Equity [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 10 On February 12, 2018, 15% $3 35% 5% $1 $7.0 49.99%. On November 15, 2019, 50.01% $8,000,000 may $8,000,000 On August 24, 2020, $5,224,423, $324,423 $4,900,000 October 15, 2020, $8,000,000 $250,000 8 no $750,000 September 1, 2020 $500,000. August 24, 2020 March 31, 2020 5,224,423 $1,895,434 March 31, 2020 The Company granted forbearance of the June 1, 2020 19 August 4, 2020, $250,000 twelve September 2020 ( 8 9 $189,423 On September 30, 2020, second $500,000 September 30, 2020 4,350,000 On October 15, 2020 $4,350,000 October 15, 2020, $4,350,000 December 8, 2020. $4,350,000 $250,000, $4,350,000 December 8, 2020. October 24, 2020, $250,000 October 29, 2020.

Note 11 - Sale of Membership In

Note 11 - Sale of Membership Interests in Nevada Subsidiaries	6 Months Ended
	Sep. 30, 2020
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 11 On November 15, 2019, 75% $3.0 $3.0 $470,000 5 8% 8% February 28, 2019 ( 6 On March 24, 2020, 100% $4,000,000 $4,000,000 8% 36 On July 24, 2020, 8% "July 24 $500,000 may 8% February 28, 2019 ( 6 July 24 $4,000,000 3 July 24 125,000 July 24 5 The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company's wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, 100% August 10, 2020, $300,000 $300,000 0% October 23, 2017, Because the moratorium on license transfers has been lifted, the Company determined that the Teco Facility and Nopah Facility qualify for presentation as discontinued operations, and the income, assets, and cash flows of the Teco Subsidiaries and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's condensed consolidated financial statements.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	6 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12 Capital Transactions Subsequent to September 30, 2020, 1,246,750 $0.03 $33,663, $3,740 Note Receivable On October 15, 2020 $4,350,000 October 15, 2020 August 24, 2020 10 $4,350,000 December 8, 2020. $4,350,000 $250,000, $4,350,000 December 8, 2020. October 24, 2020, $250,000 October 29, 2020. Note Payable On October 5, 2020, $150,000 8% May 7, 2020 ( 5 On October 20, 2020, $75,000 8% July 24, 2020 ( 5 $200,000.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2021. March 31, 2020 not 10 March 31, 2020
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the comparative period amounts to conform to the current period presentation. Certain items on the unaudited balance sheets and statements of operations and cash flows have been reclassified to conform with current period presentation. The assets, liabilities, income, and cash flows of GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified to discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 10 11
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations Refer to Note 3.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not No September 30, 2020
Inventory, Policy [Policy Text Block]	Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not
Earnings Per Share, Policy [Policy Text Block]	Earnings/(loss) per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 153,637,853 158,404,020 September 30, 2020 March 31, 2020 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recently Adopted Standards In June 2016, No. 2016 13, 326 2016 13" 326 326 326 2016 13 not not December 15, 2022, In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, April 1, 2020. not All other newly issued accounting pronouncements but not not

Note 3 - Discontinued Operati_2

Note 3 - Discontinued Operations (Tables)	6 Months Ended
	Sep. 30, 2020
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	September 30, 2020 March 31, 2020 Continuing Nevada Subsidiaries Total Continuing Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 545,020 $ 149,221 $ 694,241 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 346,058 346,058 - 117,967 117,967 Inventory, net - 1,439,320 1,439,320 - 1,445,839 1,445,839 Prepaid and other current assets 18,776 62,438 81,214 18,776 42,109 60,885 Note receivable 4,350,000 - 4,350,000 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 4,913,796 1,997,037 6,910,833 5,245,605 1,755,275 7,000,880 Property and equipment, net 31,278 5,113,829 5,145,107 37,821 5,496,012 5,533,833 Intangible assets, net 1,545,355 571,265 2,116,620 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 81,504 81,504 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 6,490,429 $ 7,763,635 $ 14,254,064 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 2,346,652 $ 607,766 $ 2,954,418 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 479,255 79,123 558,378 366,865 30,787 397,652 Accrued expenses 1,205,248 48,010 1,253,258 813,618 74,394 888,012 Notes payable, net 6,428,278 485,000 6,913,278 5,054,728 480,000 5,534,728 Indebtedness to related parties 710,075 - 710,075 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable 620,856 - 620,856 592,982 - 592,982 Finance lease obligations, current - 128,212 128,212 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 11,790,364 1,348,111 13,138,475 9,479,677 1,406,080 10,885,757 Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,465,160 3,465,160 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 11,790,364 $ 4,813,271 $ 16,603,635 $ 9,479,677 $ 4,961,685 $ 14,441,362 For the Three Months Ended September 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,264,271 $ 1,264,271 $ - $ 1,548,705 $ 1,548,705 Cost of goods sold - (859,068 ) (859,068 ) - (2,237,779 ) (2,237,779 ) Gross profit/(loss) - 405,203 405,203 - (689,074 ) (689,074 ) General and administrative expenses 491,818 81,464 573,282 1,291,232 536,814 1,828,046 INCOME/(LOSS) FROM OPERATIONS (491,818 ) 323,739 (168,079 ) (1,291,232 ) (1,225,888 ) (2,517,120 ) OTHER INCOME/(EXPENSE) Interest expense (410,946 ) (128,201 ) (539,147 ) (352,736 ) (185,599 ) (538,335 ) Other income/(expense) (1,750 ) (77,448 ) (79,198 ) 92,707 (23,250 ) 69,457 Total other expense (412,696 ) (205,649 ) (618,345 ) (260,029 ) (208,849 ) (468,878 ) INCOME/(LOSS) BEFORE INCOME TAXES (904,514 ) 118,090 (786,424 ) (1,551,261 ) (1,434,737 ) (2,985,998 ) Income tax expense (19,034 ) - (19,034 ) 57,392 - 57,392 NET INCOME/(LOSS) $ (923,548 ) $ 118,090 $ (805,458 ) $ (1,493,869 ) $ (1,434,737 ) $ (2,928,606 ) For the Six Months Ended September 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,815,468 $ 1,815,468 $ - $ 2,459,381 $ 2,459,381 Cost of goods sold - (1,350,863 ) (1,350,863 ) - (2,862,148 ) (2,862,148 ) Gross profit/(loss) - 464,605 464,605 - (402,767 ) (402,767 ) General and administrative expenses 1,007,071 370,920 1,377,991 3,082,697 1,012,737 4,095,434 INCOME/(LOSS) FROM OPERATIONS (1,007,071 ) 93,685 (913,386 ) (3,082,697 ) (1,415,504 ) (4,498,201 ) OTHER INCOME/(EXPENSE) Interest expense (1,082,874 ) (261,143 ) (1,344,017 ) (664,937 ) (373,809 ) (1,038,746 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other income/(expense) (3,374 ) (77,448 ) (80,822 ) 92,707 (23,250 ) 69,457 Total other expense (1,372,307 ) (338,591 ) (1,710,898 ) (572,230 ) (397,059 ) (969,289 ) LOSS BEFORE INCOME TAXES (2,379,378 ) (244,906 ) (2,624,284 ) (3,654,927 ) (1,812,563 ) (5,467,490 ) Income tax expense (27,874 ) - (27,874 ) - - - NET LOSS $ (2,407,252 ) $ (244,906 ) $ (2,652,158 ) $ (3,654,927 ) $ (1,812,563 ) $ (5,467,490 ) For the Three Months Ended September 30, 2020 2019 GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations Sales revenue $ - $ 1,264,271 $ 1,264,271 $ 377,007 $ 1,171,698 $ 1,548,705 Cost of goods sold - (859,068 ) (859,068 ) (380,629 ) (1,857,150 ) (2,237,779 ) Gross profit/(loss) - 405,203 405,203 (3,622 ) (685,452 ) (689,074 ) General and administrative expenses - 81,464 81,464 424,732 112,082 536,814 INCOME/(LOSS) FROM OPERATIONS - 323,739 323,739 (428,354 ) (797,534 ) (1,225,888 ) OTHER EXPENSE Interest expense - (128,201 ) (128,201 ) (62,777 ) (122,822 ) (185,599 ) Other expense - (77,448 ) (77,448 ) - (23,250 ) (23,250 ) Total other expense - (205,649 ) (205,649 ) (62,777 ) (146,072 ) (208,849 ) INCOME/(LOSS) BEFORE INCOME TAXES - 118,090 118,090 (491,131 ) (943,606 ) (1,434,737 ) Income tax expense - - - - - - NET INCOME/(LOSS) $ - $ 118,090 $ 118,090 $ (491,131 ) $ (943,606 ) $ (1,434,737 ) For the Six Months Ended September 30, 2020 2019 GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations Sales revenue $ - $ 1,815,468 $ 1,815,468 $ 377,007 $ 2,082,374 $ 2,459,381 Cost of goods sold - (1,350,863 ) (1,350,863 ) (380,629 ) (2,481,519 ) (2,862,148 ) Gross profit/(loss) - 464,605 464,605 (3,622 ) (399,145 ) (402,767 ) General and administrative expenses - 370,920 370,920 626,571 386,166 1,012,737 INCOME/(LOSS) FROM OPERATIONS - 93,685 93,685 (630,193 ) (785,311 ) (1,415,504 ) OTHER EXPENSE Interest expense - (261,143 ) (261,143 ) (125,372 ) (248,437 ) (373,809 ) Debt default penalty - - - - - - Other expense - (77,448 ) (77,448 ) - (23,250 ) (23,250 ) Total other expense - (338,591 ) (338,591 ) (125,372 ) (271,687 ) (397,059 ) LOSS BEFORE INCOME TAXES - (244,906 ) (244,906 ) (755,565 ) (1,056,998 ) (1,812,563 ) Income tax expense - - - - - - NET LOSS $ - $ (244,906 ) $ (244,906 ) $ (755,565 ) $ (1,056,998 ) $ (1,812,563 )
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2020 March 31, 2020 Raw materials $ 2,677 $ 91,465 Work in progress 789,482 1,166,511 Finished goods 653,314 466,319 Subtotal 1,445,473 1,724,295 Allowance to reduce inventory to net realizable value (6,153 ) (278,456 ) Total inventory, net $ 1,439,320 $ 1,445,839
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]	Year Ending March 31, Finance Leases 2021 (6 months) $ 266,188 2022 544,296 2023 560,625 2024 577,444 2025 594,767 Thereafter 3,781,102 Total minimum lease payments 6,324,422 Less: Amount representing interest (2,731,050 ) Present value of minimum lease payments 3,593,372 Less: Current maturities of capital lease obligations (128,212 ) Long-term capital lease obligations $ 3,465,160

Note 5 - Notes Payable and Li_2

Note 5 - Notes Payable and Line of Credit (Tables)	6 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Debt [Table Text Block]	As of September 30, 2020 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (1,919 ) $ 367,526 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 125,000 - 125,000 8% Note Payable dated May 7, 2020 (Note 5) 150,000 - 150,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (7,705 ) 1,249,295 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 - 1,271,863 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 3,264,594 - 3,264,594 Total short-term notes payable 6,922,902 (9,624 ) 6,913,278 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short-term notes payable classified as continuing operations $ 6,437,902 $ (9,624 ) $ 6,428,278

Note 1 - Background and Signi_2

Note 1 - Background and Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020
Impairment of Long-Lived Assets Held-for-use	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	153,637,853	158,404,020

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Mar. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance	$ (100,056,626)		$ (97,387,205)
Working Capital (Deficit)	(6,227,642)		(3,884,877)
Net Cash Provided by (Used in) Operating Activities, Total	(212,854)	$ (3,546,457)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	(10,602)	$ (1,758,120)
Discontinued Operations [Member]
Working Capital (Deficit)	$ 648,926		$ 349,195

Note 3 - Discontinued Operati_3

Note 3 - Discontinued Operations (Details Textual) - USD ($)	6 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Apr. 01, 2019
Lessee, Operating Lease, Discount Rate	17.00%
Operating Lease, Cost	$ 3,243
Operating Lease, Interest Expense	1,242
Operating Lease, Right-of-Use Asset, Amortization Expense	2,001
Discontinued Operations [Member]
Operating Lease, Right-of-Use Asset		$ 26,685
Finance Lease Costs	286,436
Finance Lease, Interest Expense	209,086
Finance Lease, Right-of-Use Asset, Amortization	77,350
Continuing Operations [Member]
Operating Lease, Right-of-Use Asset
Operating Lease, Cost	3,243
Operating Lease, Interest Expense	1,242
Operating Lease, Right-of-Use Asset, Amortization Expense	$ 2,001
Minimum [Member]
Lessee, Finance Lease, Discount Rate	10.20%
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 182,624
Operating Lease, Liability, Total			$ 190,173
GB Sciences Louisiana, LLC [Member]
Disposal Group, Including Discontinued Operation, Assets, Total	$ 0	0
Disposal Group, Including Discontinued Operation, Liabilities, Total	$ 0	$ 0

Note 3 - Discontinued Operati_4

Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Mar. 31, 2020
Cash and cash equivalents	$ 545,020		$ 545,020		$ 2,406
Prepaid and other current assets	18,776		18,776		18,776
Note receivable	4,350,000		4,350,000		5,224,423
TOTAL CURRENT ASSETS	6,910,833		6,910,833		7,000,880
Property and equipment, net	31,278		31,278		37,821
Intangible assets, net	1,545,355		1,545,355		1,128,702
TOTAL ASSETS	14,254,064		14,254,064		14,352,868
Accounts payable	2,346,652		2,346,652		1,913,049
Accrued interest	479,255		479,255		366,865
Accrued liabilities	1,205,248		1,205,248		813,618
Notes payable, net	6,428,278		6,428,278		5,054,728
Indebtedness to related parties	710,075		710,075		586,512
Note payable to related party					151,923
Income tax payable	620,856		620,856		592,982
TOTAL CURRENT LIABILITIES	13,138,475		13,138,475		10,885,757
TOTAL LIABILITIES	16,603,635		16,603,635		14,441,362
Sales revenue
Cost of goods sold
Gross profit/(loss)
General and administrative expenses	491,818	1,291,232	1,007,071	3,082,697
INCOME/(LOSS) FROM OPERATIONS	(491,818)	(1,291,232)	(1,007,071)	(3,082,697)
Interest expense	(410,946)	(352,736)	(1,082,874)	(664,937)
Other income/(expense)	(1,750)	92,707	(3,374)	92,707
Total other expense	(412,696)	(260,029)	(1,372,307)	(572,230)
INCOME/(LOSS) BEFORE INCOME TAXES	(904,514)	(1,551,261)	(2,379,378)	(3,654,927)
Income tax benefit/(expense)	(19,034)	57,392	(27,874)
Net loss	(805,458)	(2,928,606)	(2,652,158)	(5,467,490)
Debt default penalty			(286,059)
NET INCOME/(LOSS)	118,090	(1,434,737)	(244,906)	(1,812,563)
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Inventory, net	1,439,320		1,439,320		1,445,839
Finance lease obligations, current	128,212		128,212
Long-term capital lease obligations, finance leases	3,465,160		3,465,160
Sales revenue	1,264,271	1,548,705	1,815,468	2,459,381
Cost of goods sold	(859,068)	(2,237,779)	(1,350,863)	(2,862,148)
Gross profit/(loss)	405,203	(689,074)	464,605	(402,767)
General and administrative expenses	81,464	536,814	370,920	1,012,737
INCOME/(LOSS) FROM OPERATIONS	323,739	(1,225,888)	93,685	(1,415,504)
Interest expense	(128,201)	(185,599)	(261,143)	(373,809)
Other expense	(77,448)	(23,250)	(77,448)	(23,250)
Total other expense	(205,649)	(208,849)	(338,591)	(397,059)
INCOME/(LOSS) BEFORE INCOME TAXES	118,090	(1,434,737)	(244,906)	(1,812,563)
Income tax expense
NET INCOME/(LOSS)	118,090	(1,434,737)	(244,906)	(1,812,563)
Debt default penalty
GB Sciences Louisiana, LLC [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Sales revenue		377,007		377,007
Cost of goods sold		(380,629)		(380,629)
Gross profit/(loss)		(3,622)		(3,622)
General and administrative expenses		424,732		626,571
INCOME/(LOSS) FROM OPERATIONS		(428,354)		(630,193)
Interest expense		(62,777)		(125,372)
Other expense
Total other expense		(62,777)		(125,372)
INCOME/(LOSS) BEFORE INCOME TAXES		(491,131)		(755,565)
Income tax expense
NET INCOME/(LOSS)		(491,131)		(755,565)
Debt default penalty
Nevada Subsidiaries [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Sales revenue	1,264,271	1,171,698	1,815,468	2,082,374
Cost of goods sold	(859,068)	(1,857,150)	(1,350,863)	(2,481,519)
Gross profit/(loss)	405,203	(685,452)	464,605	(399,145)
General and administrative expenses	81,464	112,082	370,920	386,166
INCOME/(LOSS) FROM OPERATIONS	323,739	(797,534)	93,685	(785,311)
Interest expense	(128,201)	(122,822)	(261,143)	(248,437)
Other expense	(77,448)	(23,250)	(77,448)	(23,250)
Total other expense	(205,649)	(146,072)	(338,591)	(271,687)
INCOME/(LOSS) BEFORE INCOME TAXES	118,090	(943,606)	(244,906)	(1,056,998)
Income tax expense
NET INCOME/(LOSS)	118,090	(943,606)	(244,906)	(1,056,998)
Debt default penalty
Continuing Operations [Member]
Cash and cash equivalents	545,020		545,020		2,406
Accounts receivable, net
Inventory, net
Prepaid and other current assets	18,776		18,776		18,776
Note receivable	4,350,000		4,350,000		5,224,423
TOTAL CURRENT ASSETS	4,913,796		4,913,796		5,245,605
Property and equipment, net	31,278		31,278		37,821
Intangible assets, net	1,545,355		1,545,355		1,128,702
Deposits and other noncurrent assets
Operating lease right-of-use assets, net
TOTAL ASSETS	6,490,429		6,490,429		6,412,128
Accounts payable	2,346,652		2,346,652		1,913,049
Accrued interest	479,255		479,255		366,865
Accrued liabilities	1,205,248		1,205,248		813,618
Notes payable, net	6,428,278		6,428,278		5,054,728
Indebtedness to related parties	710,075		710,075		586,512
Note payable to related party					151,923
Income tax payable	620,856		620,856		592,982
Finance lease obligations, current
Operating lease obligations, current
TOTAL CURRENT LIABILITIES	11,790,364		11,790,364		9,479,677
Operating lease obligations, long term
Long-term capital lease obligations, finance leases
TOTAL LIABILITIES	11,790,364		11,790,364		9,479,677
Sales revenue
Cost of goods sold
Gross profit/(loss)
General and administrative expenses	491,818	1,291,232	1,007,071	3,082,697
INCOME/(LOSS) FROM OPERATIONS	(491,818)	(1,291,232)	(1,007,071)	(3,082,697)
Interest expense	(410,946)	(352,736)	(1,082,874)	(664,937)
Other income/(expense)	(1,750)	92,707	(3,374)	92,707
Total other expense	(412,696)	(260,029)	(1,372,307)	(572,230)
INCOME/(LOSS) BEFORE INCOME TAXES	(904,514)	(1,551,261)	(2,379,378)	(3,654,927)
Income tax benefit/(expense)	(19,034)	57,392	(27,874)
Net loss	(923,548)	(1,493,869)	(2,407,252)	(3,654,927)
Debt default penalty			(286,059)
Discontinued Operations [Member]
Cash and cash equivalents	149,221		149,221		149,360
Accounts receivable, net	346,058		346,058		117,967
Inventory, net	1,439,320		1,439,320		1,445,839
Prepaid and other current assets	62,438		62,438		42,109
Note receivable
TOTAL CURRENT ASSETS	1,997,037		1,997,037		1,755,275
Property and equipment, net	5,113,829		5,113,829		5,496,012
Intangible assets, net	571,265		571,265		571,264
Deposits and other noncurrent assets	81,504		81,504		91,504
Operating lease right-of-use assets, net					26,685
TOTAL ASSETS	7,763,635		7,763,635		7,940,740
Accounts payable	607,766		607,766		646,865
Accrued interest	79,123		79,123		30,787
Accrued liabilities	48,010		48,010		74,394
Notes payable, net	485,000		485,000		480,000
Indebtedness to related parties
Note payable to related party
Income tax payable
Finance lease obligations, current	128,212		128,212		166,769
Operating lease obligations, current					7,265
TOTAL CURRENT LIABILITIES	1,348,111		1,348,111		1,406,080
Operating lease obligations, long term					22,515
Long-term capital lease obligations, finance leases	3,465,160		3,465,160		3,533,090
TOTAL LIABILITIES	4,813,271		4,813,271		4,961,685
Sales revenue	1,264,271	1,548,705	1,815,468	2,459,381
Cost of goods sold	(859,068)	(2,237,779)	(1,350,863)	(2,862,148)
Gross profit/(loss)	405,203	(689,074)	464,605	(402,767)
General and administrative expenses	81,464	536,814	370,920	1,012,737
INCOME/(LOSS) FROM OPERATIONS	323,739	(1,225,888)	93,685	(1,415,504)
Interest expense	(128,201)	(185,599)	(261,143)	(373,809)
Other income/(expense)	(77,448)	(23,250)	(77,448)	(23,250)
Total other expense	(205,649)	(208,849)	(338,591)	(397,059)
INCOME/(LOSS) BEFORE INCOME TAXES	118,090	(1,434,737)	(244,906)	(1,812,563)
Income tax benefit/(expense)
Net loss	118,090	(1,434,737)	(244,906)	(1,812,563)
Debt default penalty
Segment, Continuing and Discontinued Operations [Member]
Cash and cash equivalents	694,241		694,241		151,766
Accounts receivable, net	346,058		346,058		117,967
Inventory, net	1,439,320		1,439,320		1,445,839
Prepaid and other current assets	81,214		81,214		60,885
Note receivable	4,350,000		4,350,000		5,224,423
TOTAL CURRENT ASSETS	6,910,833		6,910,833		7,000,880
Property and equipment, net	5,145,107		5,145,107		5,533,833
Intangible assets, net	2,116,620		2,116,620		1,699,966
Deposits and other noncurrent assets	81,504		81,504		91,504
Operating lease right-of-use assets, net					26,685
TOTAL ASSETS	14,254,064		14,254,064		14,352,868
Accounts payable	2,954,418		2,954,418		2,559,914
Accrued interest	558,378		558,378		397,652
Accrued liabilities	1,253,258		1,253,258		888,012
Notes payable, net	6,913,278		6,913,278		5,534,728
Indebtedness to related parties	710,075		710,075		586,512
Note payable to related party					151,923
Income tax payable	620,856		620,856		592,982
Finance lease obligations, current	128,212		128,212		166,769
Operating lease obligations, current					7,265
TOTAL CURRENT LIABILITIES	13,138,475		13,138,475		10,885,757
Operating lease obligations, long term					22,515
Long-term capital lease obligations, finance leases	3,465,160		3,465,160		3,533,090
TOTAL LIABILITIES	16,603,635		16,603,635		$ 14,441,362
Sales revenue	1,264,271	1,548,705	1,815,468	2,459,381
Cost of goods sold	(859,068)	(2,237,779)	(1,350,863)	(2,862,148)
Gross profit/(loss)	405,203	(689,074)	464,605	(402,767)
General and administrative expenses	573,282	1,828,046	1,377,991	4,095,434
INCOME/(LOSS) FROM OPERATIONS	(168,079)	(2,517,120)	(913,386)	(4,498,201)
Interest expense	(539,147)	(538,335)	(1,344,017)	(1,038,746)
Other income/(expense)	(79,198)	69,457	(80,822)	69,457
Total other expense	(618,345)	(468,878)	(1,710,898)	(969,289)
INCOME/(LOSS) BEFORE INCOME TAXES	(786,424)	(2,985,998)	(2,624,284)	(5,467,490)
Income tax benefit/(expense)	(19,034)	57,392	(27,874)
Net loss	$ (805,458)	$ (2,928,606)	(2,652,158)	(5,467,490)
Debt default penalty			$ (286,059)

Note 3 - Discontinued Operati_5

Note 3 - Discontinued Operations - Schedule of Inventory (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] - USD ($)	Sep. 30, 2020	Mar. 31, 2020
Raw materials	$ 2,677	$ 91,465
Work in progress	789,482	1,166,511
Finished goods	653,314	466,319
Subtotal	1,445,473	1,724,295
Allowance to reduce inventory to net realizable value	(6,153)	(278,456)
Total inventory, net	$ 1,439,320	$ 1,445,839

Note 3 - Discontinued Operati_6

Note 3 - Discontinued Operations - Future Minimum Lease Payments (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]	Sep. 30, 2020USD ($)
2021 (6 months), finance leases	$ 266,188
2022, finance leases	544,296
2023, finance leases	560,625
2024, finance leases	577,444
2025, finance leases	594,767
Thereafter, finance leases	3,781,102
Total minimum lease payments, finance leases	6,324,422
Less: Amount representing interest, finance leases	(2,731,050)
Present value of minimum lease payments, finance leases	3,593,372
Less: Current maturities of capital lease obligations, finance leases	(128,212)
Long-term capital lease obligations, finance leases	$ 3,465,160

Note 4 - Leases (Continuing O_2

Note 4 - Leases (Continuing Operations) (Details Textual) - USD ($)	6 Months Ended
	Sep. 30, 2020	Apr. 01, 2019
Operating Lease, Cost	$ 3,243
Operating Lease, Interest Expense	1,242
Operating Lease, Right-of-Use Asset, Amortization Expense	$ 2,001
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset		$ 182,624
Operating Lease, Liability, Total		$ 190,173

Note 5 - Notes Payable and Li_3

Note 5 - Notes Payable and Line of Credit (Details Textual)	May 07, 2020USD ($)$ / sharesshares	Oct. 23, 2017USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Aug. 10, 2020USD ($)	Jul. 24, 2020USD ($)	Jun. 30, 2020USD ($)	May 06, 2020USD ($)	Mar. 24, 2020USD ($)	Nov. 27, 2019USD ($)	Oct. 23, 2019USD ($)
Proceeds from Lines of Credit, Total					$ 125,000
Payments of Debt Issuance Costs						175,000
Interest Expense, Debt, Excluding Amortization						26,804
Amortization of Debt Discount (Premium)					748,956	$ 434,750
Repriced Preexisting Warrants with Convertible Debt Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	8,002,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.04
Warrants and Rights Outstanding	$ 272,085											$ 49,525
Fair Value Adjustment of Warrants	$ 222,560
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity														$ 470,000
Proceeds from Lines of Credit, Total							$ 485,000
Line of Credit Facility, Maximum Borrowing Capacity, Increased							15,000
Interest Payable			$ 19,420	$ 19,420	19,420		19,420	$ 19,420
Long-term Line of Credit, Total			485,000	485,000	485,000		485,000	485,000
Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total													$ 4,000,000
The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage										8.00%
The July 24 Note [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity										$ 500,000
Proceeds from Lines of Credit, Total			125,000
Interest and Debt Expense, Total					1,162
The July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total										$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding										3
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage		0.00%												0.00%
Debt Instrument, Face Amount		$ 700,000
Debt Instrument, Term (Year)		3 years
Debt Instrument, Present Value			521,067	521,067	$ 521,067		521,067	521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)					20.30%
Debt Instrument, Unamortized Discount, Total			1,919	1,919	$ 1,919		1,919	1,919							$ 178,933
Repayments of Debt								330,555
Long-term Debt, Gross			$ 369,445	369,445	369,445		$ 369,445	$ 369,445
Interest Expense, Debt, Total					12,009
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition									$ 190,272
Debt Instrument, Penalty Rate Waived Upon Closing of Disposition									15.00%
Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Face Amount	$ 150,000
Debt Instrument, Unamortized Discount, Total	150,000										$ 0
Proceeds from Issuance of Long-term Debt, Net	135,000
Payments of Debt Issuance Costs	$ 15,000
Repayments of Long-term Debt, Total				$ 8,000,000
Interest and Debt Expense, Total					154,964
Interest Expense, Debt, Excluding Amortization					4,964
Amortization of Debt Discount (Premium)					$ 150,000
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License		$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of Licence		100.00%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of Licence		100.00%

Note 5 - Notes Payable and Li_4

Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($)	Sep. 30, 2020	Mar. 31, 2020	Apr. 23, 2019
Discount, short-term notes payable	$ (9,624)	$ (608,580)
Discount, short-term notes payable	(9,624)	$ (608,580)
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable	369,445
Discount, short-term notes payable	(1,919)
Carrying Value, short-term notes payable	367,526
Face Value, short-term notes payable	369,445
Discount, short-term notes payable	(1,919)
Carrying Value, short-term notes payable	367,526
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Issued to Investor on May 7, 2020 [Member]
Face Value, short-term notes payable	150,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	150,000
Face Value, short-term notes payable	150,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	150,000
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Face Value, short-term notes payable	1,257,000
Discount, short-term notes payable	(7,705)
Carrying Value, short-term notes payable	1,249,295
Face Value, short-term notes payable	1,257,000
Discount, short-term notes payable	(7,705)
Carrying Value, short-term notes payable	1,249,295
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Face Value, short-term notes payable	3,264,594		$ 2,765,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	3,264,594
Face Value, short-term notes payable	3,264,594		$ 2,765,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	3,264,594
Line of Credit [Member] | The 8% Line of Credit Dated November 27, 2019 [Member]
Face Value, short-term notes payable	485,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	485,000
Face Value, short-term notes payable	485,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	485,000
Line of Credit [Member] | The 8% Line of Credit Dated July 24, 2020 [Member]
Face Value, short-term notes payable	125,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	125,000
Face Value, short-term notes payable	125,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	125,000
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Face Value, short-term notes payable	1,271,863
Discount, short-term notes payable
Carrying Value, short-term notes payable	1,271,863
Face Value, short-term notes payable	1,271,863
Discount, short-term notes payable
Carrying Value, short-term notes payable	1,271,863
Promissory Note [Member]
Face Value, short-term notes payable	6,922,902
Discount, short-term notes payable	(9,624)
Carrying Value, short-term notes payable	6,913,278
Face Value, short-term notes payable	6,922,902
Discount, short-term notes payable	(9,624)
Carrying Value, short-term notes payable	6,913,278
Less: Notes payable classified as discontinued operations, face value	(485,000)
Less: Notes payable classified as discontinued operations, discount
Less: Notes payable classified as discontinued operations, carrying value	(485,000)
Total short-term notes payable classified as continuing operations, face value	6,437,902
Total short-term notes payable classified as continuing operations, discount	(9,624)
Total short-term notes payable classified as continuing operations, carrying value	$ 6,428,278

Note 6 - Convertible Notes (Det

Note 6 - Convertible Notes (Details Textual)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Dec. 16, 2019USD ($)$ / sharesshares	Nov. 27, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / sharesshares	Oct. 30, 2019USD ($)$ / sharesshares	Oct. 23, 2019USD ($)$ / shares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 12, 2019USD ($)$ / shares	May 28, 2019USD ($)$ / sharesshares	Apr. 23, 2019USD ($)$ / shares	Feb. 28, 2019USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	May 31, 2017USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / shares	Sep. 30, 2019USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2020USD ($)
Interest Payable, Current																$ 479,255			$ 366,865
Amortization of Debt Discount (Premium)																748,956	$ 434,750
Gain (Loss) on Extinguishment of Debt, Total																	(124,158)
Interest Expense, Debt, Excluding Amortization																	26,804
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty	15.00%
Litigation Settlement, Amount Awarded to Other Party	$ 3,264,594
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 0.25
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 1
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants														4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.60	$ 0.60
Warrants and Rights Outstanding, Term (Year)														3 years	3 years
Class of Warrant or Right, Issued (in shares) | shares															8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares															1
Warrants Related to July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants													4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares													$ 0.65					$ 0.60
Warrants and Rights Outstanding, Term (Year)																		3 years
Class of Warrant or Right, Issued (in shares) | shares																		28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																		1
Convertible Notes Payable [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature																$ 150,000	$ 133,806
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note														$ 1,000
Debt Instrument, Interest Rate, Stated Percentage														6.00%
Debt Instrument, Face Amount															$ 2,000,000
Debt Instrument, Term (Year)															3 years
Debt Instrument, Unamortized Discount, Total															$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature															904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants															$ 1,029,003
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments														4,000	8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares														$ 0.25
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note													$ 1,000
Debt Instrument, Face Amount																		$ 7,201,000
Debt Instrument, Term (Year)													3 years					3 years
Debt Instrument, Unamortized Discount, Total																7,705		$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature																		3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants																		$ 3,950,191
Long-term Debt, Gross																1,249,295
Interest Payable, Current																234,998
Interest Expense, Debt, Total																185,448
Amortization of Debt Discount (Premium)																147,635
Debt Default, Short-term Debt, Amount																997,000
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments													4,000					28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares													$ 0.25
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 0.0375	$ 0.06					$ 0.17
Debt Instrument, Face Amount											$ 2,765,000					3,264,594
Debt Instrument, Unamortized Discount, Total											265,000
Interest Expense, Debt, Total																275,310
Amortization of Debt Discount (Premium)																29,831
Debt Conversion, Original Debt, Amount					$ 50,000	$ 75,000													125,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares					1,333,333	1,250,000
Short-term Debt, Total																3,264,594
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total											440,000
Payments for Brokerage Fees											$ 175,000
Induced Conversion of Convertible Debt Expense						$ 64,706
Debt Instrument, Debt Default, Interest Rate Penalty		10.00%
Debt Instrument, Debt Default, Interest Expense		$ 9,559
Debt Instrument, Debt Default, Principal Expense		$ 276,500
Debt Instrument, Debt Default, Increase in Principal Amount, Percent		10.00%
Interest Expense, Debt, Pre-judgment Interest																140,833
Interest Expense, Debt, Post-judgment Interest																104,646
Debt Instrument, Unamortized Discount (Premium), Net, Total																0
Promissory Note [Member]
Debt Instrument, Face Amount																6,922,902
Short-term Debt, Total																6,913,278
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage													6.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage				8.00%					8.00%	8.00%		8.00%
Debt Instrument, Face Amount												$ 1,500,000
Debt Instrument, Unamortized Discount, Total			$ 584,842					$ 9,579		$ 17,225						0
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 92,796		$ 133,806			$ 176,471
Long-term Debt, Gross			687,021													1,271,863
Interest Expense, Debt, Total																460,495
Amortization of Debt Discount (Premium)			57,551													409,481
Debt Conversion, Original Debt, Amount			120,000					110,000		170,000
Debt Instrument, Increase (Decrease), Net, Total			(62,449)	$ 30,000				(100,421)	100,000	(152,775)
Short-term Debt, Total			$ 1,271,863	1,361,863			$ 1,269,067	$ 1,361,863	1,338,057	$ 1,330,000
Proceeds from Related Party Debt									100,000
Debt Instrument, Increase, Accrued Interest									41,863
Gain (Loss) on Extinguishment of Debt, Total				$ 0					$ (124,158)										$ (92,796)
Interest Expense, Debt, Excluding Amortization																$ 51,014
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Minimum [Member]
Days to Cure Breach of Default After Notification From Lender																5
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Maximum [Member]
Days to Cure Breach of Default After Notification From Lender																10
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent												100.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments												8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 0.04	$ 0.04			$ 0.08	$ 0.11	$ 0.11	$ 0.17		$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			3,000,000					1,000,000		1,000,000

Note 7 - Capital Transactions (

Note 7 - Capital Transactions (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Apr. 01, 2020
Proceeds from Warrant Exercises		$ 151,202	$ 944,975
Class of Warrant or Right, Outstanding (in shares)	79,488,161	79,488,161
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	13,366,334	13,366,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 0.28	$ 0.28
Scientist and Researcher [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	3,500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 0.03
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value	$ 105,000
Scientist and Researcher [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.25	0.25
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1	$ 1
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Exercises in Period (in shares)		4,991,084
Proceeds from Warrant Exercises		$ 136,081
Brokerage Fees for Issuance of Common Stock and Warrants		$ 15,121
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.03
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.05

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual)	Sep. 17, 2020USD ($)	Aug. 24, 2020USD ($)	Aug. 04, 2020USD ($)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Sep. 18, 2017USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)
The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Convertible Notes Payable [Member]
Debt Instrument, Debt Default, Interest Rate Penalty					10.00%
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party				$ 3,264,594
Debt Instrument, Debt Default, Interest Rate Penalty				15.00%
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Convertible Notes Payable [Member]
Debt Instrument, Balance Due, Including Accrued Post-judgment Interest							$ 3,369,240	$ 3,369,240
Debt Instrument, Accrued Post-judgment Interest							$ 104,646	104,646
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value					$ 73,050
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member]
Payments for Legal Settlements	$ 25,000
Reduction in Cost Basis of Fixed Asset Related to Litigation	$ 48,050
Agreement With Louisiana State University AgCenter [Member]
Term of Agreement (Year)						5 years	3 years
Option to Renew Agreement, Amount						2
Term of Agreement, Renewal (Year)						5 years
Research and Development Expense, Total						$ 500,000	$ 250,000	$ 750,000
Annual Research Contributions		$ 250,000	$ 250,000

Note 9 - Related Party Transa_2

Note 9 - Related Party Transactions (Details Textual) - USD ($)	Sep. 30, 2020	Aug. 04, 2020	Mar. 31, 2020
Notes Payable, Related Parties, Current			$ 151,923
John Davis [Member]
Due to Related Parties, Total		$ 189,423
Notes Payable, Related Parties, Current	151,923
Officers and Directors [Member]
Due to Related Parties, Total	710,075
Reimbursement for Business Expense, Related Parties	65,858
Officer [Member]
Unpaid Wages, Related Parties	532,130
Director [Member]
Unpaid Wages, Related Parties	$ 112,087

Note 10 - Sale of Membership _2

Note 10 - Sale of Membership Interests in GB Sciences Louisiana, LLC (Details Textual) - USD ($)	Oct. 29, 2020	Sep. 30, 2020	Aug. 24, 2020	Aug. 04, 2020	Nov. 15, 2019	Feb. 12, 2018	Oct. 15, 2020	Mar. 31, 2020	Sep. 30, 2020	Aug. 23, 2020
John Davis [Member]
Due to Related Parties, Total				$ 189,423
Agreement With Louisiana State University AgCenter [Member]
Annual Research Contributions			$ 250,000	$ 250,000
GB Sciences Louisiana, LLC [Member]
Proceeds from Divestiture of Businesses					$ 8,000,000
Earnout Payments					$ 8,000,000
Proceeds from Collection of Notes Receivable		$ 500,000
Notes Receivable, Net, Scheduled Payments			$ 500,000							$ 750,000
Financing Receivable, after Allowance for Credit Loss, Total		$ 4,350,000						$ 5,224,423	$ 4,350,000
Gain (Loss) on Modification of Note Receivable								$ (1,895,434)
GB Sciences Louisiana, LLC [Member] | Subsequent Event [Member]
Notes Receivable, Not Yet Collectible							$ 4,350,000
Notes Receivable, Due Date Extended							4,350,000
Notes Receivable, Amount for Which Proof of Funds is Required							4,350,000
Notes Receivable, Escrow Deposit Required of Other Party							250,000
Notes Receivable, Escrow Payment Received	$ 250,000
GB Sciences Louisiana, LLC [Member] | Forecast [Member]
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness							5,224,423
Debt Instrument, Decrease, Forgiveness							324,423
Proceeds from Collection of Notes Receivable							4,900,000
Note Receivable Satisfied							8,000,000
Annual Research Contribution Commitment to LSU Assumed by Counter Party							$ 250,000
Wellcana Group, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners						49.99%
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership					50.01%	15.00%
Sale of Stock, Consideration Received on Transaction						$ 3,000,000			$ 7,000,000
Sale of Stock, Percentage of Ownership Available For Sale						35.00%
Sale of Stock, Percentage of Available Stock For Sale, Percent to be Sold Per Transaction						5.00%
Sale of Stock, Consideration Received Per Transaction						$ 1,000,000

Note 11 - Sale of Membership _2

Note 11 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual)	Mar. 24, 2020USD ($)	Nov. 27, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Jul. 24, 2020USD ($)	Dec. 06, 2019USD ($)	Oct. 23, 2017
Proceeds from Lines of Credit, Total				$ 125,000
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%
Proceeds from Divestiture of Businesses	$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total	$ 4,000,000
Notes Receivable, Interest Rate	8.00%
Notes Receivable, Term of Monthly Installments (Month)	3 years
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 470,000
Proceeds from Lines of Credit, Total						$ 485,000
Teco Note [Member] | Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 470,000
Debt Instrument, Interest Rate, Stated Percentage								8.00%
The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage							8.00%
The July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total							$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding							3
The July 24 Note [Member] | Secured Debt [Member] | AJE Management, LLC [Member]
Line of Credit Facility, Maximum Borrowing Capacity							$ 500,000
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Proceeds from Lines of Credit, Total			$ 125,000
July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total							$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding							3
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage		0.00%							0.00%
Teco [Member]
Sale of Stock, Percentage of Ownership		75.00%
Sale of Stock, Consideration Received on Transaction		$ 3,000,000
Sale of Stock, Additional Earn-out Payments		$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership		100.00%
Sale of Stock, Consideration Received on Transaction		$ 300,000
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Sale of Stock, Consideration to Be Received By Means of Debt Reduction		$ 300,000

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)

Oct. 29, 2020

Oct. 20, 2020

Oct. 05, 2020

Nov. 12, 2020

Nov. 12, 2020

Sep. 30, 2020

Sep. 30, 2020

Sep. 30, 2020

Sep. 30, 2019

Oct. 15, 2020

Jul. 24, 2020

May 07, 2020

Proceeds from Lines of Credit, Total

$ 125,000

The July 24 Note [Member]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

The July 24 Note [Member] | Revolving Credit Facility [Member]

Proceeds from Lines of Credit, Total

$ 125,000

Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member]

Repayments of Long-term Debt, Total

$ 8,000,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Subsequent Event [Member]

Class of Warrant or Right, Exercised During Period (in shares)

1,246,750

Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)

$ 0.03

Proceeds from Warrant Exercises, Net of Brokerage Fees

$ 33,663

Payments of Brokerage Fees in Connection With Warrants Exercised

$ 3,740

Subsequent Event [Member] | The July 24 Note [Member] | Revolving Credit Facility [Member]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Proceeds from Lines of Credit, Total

$ 75,000

Short-term Debt, Total

$ 200,000

Subsequent Event [Member] | Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member]

Repayments of Long-term Debt, Total

$ 150,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Subsequent Event [Member] | GB Sciences Louisiana, LLC [Member]

Notes Receivable, Not Yet Collectible

$ 4,350,000

Notes Receivable, Due Date Extended

4,350,000

Notes Receivable, Amount for Which Proof of Funds is Required

4,350,000

Notes Receivable, Escrow Deposit Required of Other Party

$ 250,000

Notes Receivable, Escrow Payment Received

$ 250,000